Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis after Laparoscopic Surgery for Colorectal Cancer


Cecilia Becattini, M.D.
University of Perugia
Perugia, Italy

The benefits of extended prophylaxis for venous thromboembolism (VTE) after laparoscopic surgery for cancer is unclear. Cecilia Becattini, M.D., presents on PROLAPS-II, which is a double-blind randomized trial whose primary outcome was the composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected deep vein thrombosis or VTE-related death. In conclusion, oral rivaroxaban is more effective than a placebo for extended VTE prevention after laparoscopic surgery for colorectal cancer, without an increase in major bleeding.



Previous Article Joost Meijers and Nicola Mutch Discuss Basic Science Task Force
Next Article An Integrative Approach to Diagnose Heparin-Induced Thrombocytopenia: Development, Validation, and Implementation of a Multivariable Prediction Model
Print